On June 24, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.3/share, with turnover of HKD 64.46 million. The stock extended gains following the company's announcement that IBI3003, a GPRC5D/BCMA/CD3 trispecific antibody for the treatment of multiple myeloma, completed first patient dosing in its pivotal Phase III clinical trial.

This milestone marks a critical step toward clinical application for the innovative therapy. The catalyst has sustained market enthusiasm over consecutive sessions. Meanwhile, the broader biotechnology sector rallied in tandem, with BeiGene up 2.86% and Akeso up 1.4%, providing additional sector-level support. Separately, JPMorgan recently increased its position in the company by approximately 1.07 million shares at HKD 75.40 per share, while Xingye Securities maintained a Buy rating, citing strong pipeline data and the significance of the Pfizer partnership valued at up to USD 10.5 billion in total deal value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)